- August 4, 2022– Initial Clinical Activity Results of IMU-935 in Psoriasis Expected in the Fourth Quarter – – Unblinded Safety Data from…
- August 2, 2022NEW YORK, August 2, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- July 28, 2022– Webcast to be Held at 8:00 am ET on August 4, 2022 – NEW YORK, July 28, 2022 – Immunic,…
- July 6, 2022– Global Commercial Executive Brings 20 Years of Sales and Marketing Expertise – – Jan Van den Bossche Steps Down from Board After…
- June 28, 2022NEW YORK, June 28, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- June 15, 2022NEW YORK, June 15, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- June 8, 2022NEW YORK, June 8, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- June 2, 2022– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and…
- May 10, 2022– Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis Expected Next Month – –…
- May 5, 2022– First Time Patients Will be Treated with the Company’s Orally Available Small Molecule Modulator Targeting Restoration of Intestinal Barrier…
